Literature DB >> 31471089

Multicenter study of surgical and oncologic outcomes of extra-levator versus conventional abdominoperineal excision for lower rectal cancer.

Zhanlong Shen1, Zhaode Bu2, Ang Li3, Junyang Lu4, Liyu Zhu5, Choon Seng Chong6, Zhidong Gao5, Kewei Jiang5, Shan Wang5, Fei Li7, Yi Xiao8, Jiafu Ji9, Yingjiang Ye10.   

Abstract

BACKGROUND: The surgical and oncological outcome of extra-levator abdominoperineal excision (ELAPE) procedure remains unclear in low rectal cancer.
METHODS: A total of 194 cases of rectal cancer patients underwent ELAPE or conventional abdominoperineal excision (APE) procedure were analyzed in four hospitals' databases from January 2010 to December 2015. Clinicopathological data, overall survival (OS), disease free survival (DFS) and local recurrence free survival (LRFS) of patients were compared between two groups.
RESULTS: The operation time spent in perineal phase was significantly shorter in the ELAPE group than that in conventional APE procedure (P < 0.001). There were more specimens with excellent or good quality in ELAPE group compared to conventional APE group (P = 0.033). Patients whom underwent ELAPE procedures showed significantly better OS, DFS and LRFS than those underwent conventional APE procedures. Patients with preoperative stage cT3∼T4 (P = 0.033, P = 0.008, P = 0,033), cN+ (P = 0.002, P < 0.001, P = 0.006) and pathological stage III-IV (P = 0.023, P = 0.008, P = 0.016) were associated with significant benefits from ELAPE procedure in terms of OS, DFS and LRFS. DFS differed significantly between two groups of patients whom got preoperative chemoradiation therapy (P = 0.009) or postoperative chemotherapy (P = 0.029). For patients of pathological stage IIII-IV without preoperative chemoradiation, ELAPE procedures resulted in statistically better OS (P = 0.018) and DFS (P = 0.030). ELAPE procedure was an independent risk factor of OS, DFS and LRFS in multivariate analysis.
CONCLUSION: Low rectal cancer patients might benefit from ELAPE procedure on both surgical and oncological outcomes, especially in patients with relatively advanced tumors, inspite of the effects of pre-operative radio- and chemotherapy.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Extra-levator abdominoperineal excision; Rectal cancer; Survival

Year:  2019        PMID: 31471089     DOI: 10.1016/j.ejso.2019.08.017

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  Continuous Negative Pressure Drainage with Intermittent Irrigation Leaded to a Risk Reduction of Perineal Surgical Site Infection Following Laparoscopic Extralevator Abdominoperineal Excision for Low Rectal Cancer.

Authors:  Zhongbo Han; Chunxia Yang; Qingfeng Wang; Meng Wang; Xi Li; Chao Zhang
Journal:  Ther Clin Risk Manag       Date:  2021-04-22       Impact factor: 2.423

Review 2.  Extralevator abdominoperineal excision for advanced low rectal cancer: Where to go.

Authors:  Yu Tao; Jia-Gang Han; Zhen-Jun Wang
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

3.  Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).

Authors:  Zhengyang Yang; Xiao Zhang; Jie Zhang; Jiale Gao; Zhigang Bai; Wei Deng; Guangyong Chen; Yongbo An; Yishan Liu; Qi Wei; Jiagang Han; Ang Li; Gang Liu; Yi Sun; Dalu Kong; Hongwei Yao; Zhongtao Zhang
Journal:  BMC Cancer       Date:  2022-04-27       Impact factor: 4.638

4.  Long-term outcomes after extra-levator versus conventional abdominoperineal excision for low rectal cancer.

Authors:  Haoyu Zhang; Ganbin Li; Ke Cao; Zhiwei Zhai; Guanghui Wei; Chunxiang Ye; Baocheng Zhao; Zhenjun Wang; Jiagang Han
Journal:  BMC Surg       Date:  2022-06-22       Impact factor: 2.030

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.